GlassScriptPhysician profile
Mark M Allen
NPI 1265508410
$2,259.96
in general payments reported to CMS, 2019-2025
28 companies · $439 in 2025
The $439 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $245 · 2021: $320 · 2022: $263 · 2023: $191 · 2024: $350 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.82 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Mimedx Group, INC. | $261.11 | 2024-2025 | |
| Amgen INC. | $183.58 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.25 | 2019-2025 | |
| Pfizer INC. | $157.95 | 2019-2024 | |
| Hologic Sales and Service, LLC | $154.71 | 2019-2025 | Aptima |
| Daiichi Sankyo INC. | $126.52 | 2019-2025 | Injectafer |
| Coloplast Corp | $111.03 | 2025 | |
| Astellas Pharma US INC | $92.49 | 2024-2025 | Veozah |
| Evofem Biosciences, INC. | $91.45 | 2021-2025 | Phexxi, Solosec, Phexx |
| Mylan Pharmaceuticals INC. | $65.85 | 2020-2022 | |
| Roche Diagnostics Corporation | $48.47 | 2019 | |
| Organon LLC | $47.78 | 2023-2024 | Jada System, Nexplanon |
| Avion Pharmaceuticals | $40.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $40.54 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $36.69 | 2020-2022 | |
| Meditrina | $33.38 | 2025 | |
| Shield Therapeutics INC | $31.25 | 2024 | |
| Biom'Up France Sas | $29.84 | 2020 | |
| Exeltis, USA INC. | $25.85 | 2024 | Slynd |
| Coopersurgical, INC. | $23.60 | 2020-2021 | |
| Lupin INC. | $23.49 | 2019-2020 | |
| Smith+Nephew, INC. | $22.25 | 2023 | Stravix Pl |
| Agile Therapeutics, INC. | $21.09 | 2023 | Twirla |
| Exact Sciences Corporation | $19.77 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $14.66 | 2022 | |
| Millicent US INC | $13.88 | 2024 | Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $11.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.